At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 60 enrolled
Drug / intervention
Trelagliptin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment Preference for Weekly DPP-4 Inhibitors Versus Daily DPP-4 Inhibitors in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 4 clinical trial evaluating Trelagliptin and Alogliptin for Type 2 Diabetes Mellitus. Completed, enrolled 60 participants across 2 sites.
Detailed Summary
The purpose of this study is to examine the participant's preference for treatment with once-weekly dosing of DPP-4 inhibitor trelagliptin versus once-daily dosing of DPP-4 inhibitor alogliptin among the participants with type 2 diabetes mellitus who are being treated with once-daily dosing of DPP-4 inhibitor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartAug 2017
Primary CompletionFeb 2018
TodayJul 2026
First PostedJul 27, 2017
Enrollment StartAug 18, 2017
Primary CompletionFeb 9, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.9 years ago
Interventions
Trelagliptindrug
Trelagliptin tablets
Alogliptindrug
Alogliptin tablets